Publication:
Letter: mechanistic target of rapamycin inhibitors as adjuvant therapy for patients with hepatocellular carcinoma undergoing liver transplantation.

dc.contributor.authorRodríguez-Perálvarez, Manuel
dc.contributor.authorAmado, Victor
dc.contributor.authorde la Mata, Manuel
dc.date.accessioned2023-01-25T13:38:07Z
dc.date.available2023-01-25T13:38:07Z
dc.date.issued2019
dc.identifier.doi10.1111/apt.15300
dc.identifier.essn1365-2036
dc.identifier.pmid31359472
dc.identifier.urihttp://hdl.handle.net/10668/14335
dc.issue.number4
dc.journal.titleAlimentary pharmacology & therapeutics
dc.journal.titleabbreviationAliment Pharmacol Ther
dc.language.isoen
dc.organizationHospital Universitario Reina Sofía
dc.organizationHospital Universitario Reina Sofía
dc.organizationInstituto Maimónides de Investigación Biomédica de Córdoba-IMIBIC
dc.page.number478-479
dc.pubmedtypeLetter
dc.pubmedtypeComment
dc.subject.meshCarcinoma, Hepatocellular
dc.subject.meshEverolimus
dc.subject.meshHumans
dc.subject.meshLiver Neoplasms
dc.subject.meshLiver Transplantation
dc.subject.meshSirolimus
dc.titleLetter: mechanistic target of rapamycin inhibitors as adjuvant therapy for patients with hepatocellular carcinoma undergoing liver transplantation.
dc.typeresearch article
dc.volume.number50
dspace.entity.typePublication
Files